Mass spectrometry raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-02-24. Anything still debated is marked as such rather than presented as settled.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated sequences and other synthesis by-products. Mass spectrometry, typically electrospray ionization coupled to liquid chromatography, confirms the expected mass and helps detect modifications. Amino acid analysis can verify composition when residue-level confirmation is needed. Because common impurities differ from the target by only one or two residues, chromatographic resolution often matters more than a single headline purity percentage. Impurity profiles are most informative when compared against a validated reference standard.
Lyophilized material is generally reported as stable for extended periods when kept cold, dry, and protected from light. In solution, the main degradation routes for a peptide of this type are hydrolysis of peptide bonds and aggregation. The sequence contains no cysteine, so disulfide-driven oxidation is not a primary concern, though methionine and tryptophan are also absent. Stability depends on pH, buffer composition, and concentration, with acidic conditions often reported as more favorable than neutral or alkaline ones. Repeated freeze-thaw cycles can promote aggregation, and how fast degradation proceeds at room temperature in specific formulations remains an open question.
| Property | Value | Notes |
|---|---|---|
| Origin | Fragment of a protein found in human gastric juice | Sequence corresponds to a fifteen-residue portion of the parent protein |
| Sequence | GEPPPGKPADDAGLV | Single linear chain, fifteen amino acids |
| Reported molecular weight | About 1419 daltons | Value quoted consistently in supplier and review literature |
| Regulatory status | Not an approved human medicine in the US or EU | Handled and sold as a research chemical |
| Sports status | Listed as prohibited | Falls under non-approved-substance categories in anti-doping codes |
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
The principal physiological function of glyoxalase I is the detoxification of methylglyoxal, a reactive 2-oxoaldehyde that is cytostatic at low concentrations and cytotoxic at millimolar concentrations. Methylglyoxal is a by-product of normal biochemistry that is a carcinogen, a mutagen and can chemically damage several components of the cell, such as proteins and nucleic acids. Methylglyoxal is formed spontaneously from dihydroxyacetone phosphate, enzymatically by triosephosphate isomerase and methylglyoxal synthase, as also in the catabolism of threonine. To minimize the amount of toxic methylglyoxal and other reactive 2-oxoaldehydes, the glyoxalase system has evolved. The methylglyoxal reacts spontaneously with reduced glutathione (or its equivalent, trypanothione),) forming a hemithioacetal. The glyoxalase system converts such compounds into D-lactate and restored the glutathione. In this conversion, the two carbonyl carbons of the 2-oxoaldehyde are oxidized and reduced, respectively, the aldehyde being oxidized to a carboxylic acid and the acetal group being reduced to an alcohol. The glyoxalase system evolved very early in life's history and is found nearly universally through life-forms. The glyoaxalase system consists of two enzymes, glyoxalase I and glyoxalase II. The former enzyme, described here, rearranges the hemithioacetal formed naturally by the attack of glutathione on methylglyoxal into the product. Glyoxalase II hydrolyzes the product to re-form the glutathione and produce D-lactate.
== Risks == The use of sedative medications in older people generally should be avoided. These medications are associated with poorer health outcomes, including cognitive decline, fall, and bone fractures. Sedatives and hypnotics should also be avoided in people with dementia, according to the clinical guidelines known as the Medication Appropriateness Tool for Comorbid Health Conditions in Dementia (MATCH-D). The use of these medications can further impede cognitive function for people with dementia, who are also more sensitive to side effects of medications. Some hypnotics, such as low-dose doxepin, melatonin receptor agonists, and orexin receptor antagonists, may be safer and more appropriate in older adults however.
Specific glycosylation has been shown to occur after the formation of the heptpeptide aglycone. Three separate glycosyl transferases are required for the glycosylation of the teicoplanin aglycone. Tei10* catalyses the addition of GlcNAc to residue 4, followed by deacetylation by Tei2*. The acyl chain (produced by the action of Tei30* and Tei13*) is then added by Tei11*. Tei1 then adds a second GlcNAc to the β-hydroxyl group of residue 6, followed by mannosylation of residue 7 catalysed by Tei3*.
Sources: en.wikipedia.org
Collagen alpha-4(IV) chain is a protein that in humans is encoded by the COL4A4 gene. This gene encodes one of the six subunits of type IV collagen, the major structural component of basement membranes. This particular collagen IV subunit, however, is only found in a subset of basement membranes. Like the other members of the type IV collagen gene family, this gene is organized in a head-to-head conformation with another type IV collagen gene so that each gene pair shares a common promoter. Mutations in this gene are associated with type II autosomal recessive Alport syndrome (hereditary glomerulonephropathy) and with familial benign hematuria (thin basement membrane disease). Two transcripts, differing only in their transcription start sites, have been identified for this gene and, as is common for collagen genes, multiple polyadenylation sites are found in the 3' UTR.
== Function == This gene encodes the alpha-1 chain of type II collagen, a fibrillar collagen found in cartilage and the vitreous humor of the eye. Type II collagen, which adds structure and strength to connective tissues, is found primarily in cartilage, the jelly-like substance that fills the eyeball (the vitreous), the inner ear, and the center portion of the discs between the vertebrae in the spine (nucleus pulposus). Three pro-alpha1(II) chains twist together to form a triple-stranded, ropelike procollagen molecule. These procollagen molecules must be processed by enzymes in the cell. Once these molecules are processed, they leave the cell and arrange themselves into long, thin fibrils that cross-link to one another in the spaces around cells. The cross-linkages result in the formation of very strong mature type II collagen fibers.
== Protein degradation == Protein degradation differs from protein catabolism. Proteins are produced and destroyed routinely as part of the normal operations of the cell. Transcription factors, proteins that help regulate protein synthesis, are targets of such degradations. Their degradation is not a significant contributor to the energy needs of the cell. The addition of ubiquitin (ubiquitylation) marks a protein for degradation via the proteasome.
Israeli airstrikes hit Iranian oil storage facilities, killing four people. Strikes on fuel depots near Tehran caused a "river of fire" to pour out along the streets, and the city became engulfed in thick black smoke, causing toxic acidic rain to fall in the surrounding area. US Central Command announced the death of a seventh US service member from an Iranian attack. The UK confirmed its forces had intercepted an Iranian drone headed towards Iraq, and declared its intention to send a Merlin helicopter to the region to detect aerial threats. According to the Iranian Red Crescent Society, 65 schools and 32 medical facilities had been targeted, and more than 10,000 civilian sites damaged. On 9 March, NATO confirmed the interception of a second ballistic missile in Turkish airspace. Turkey deployed six F-16s and air defense systems to Northern Cyprus. Trump claimed that "the war is very complete, pretty much", after speaking with Russian president Putin, and said "we already won the war in many ways." Following Syrian president Ahmed al-Sharaa's support for Lebanon's objective to disarm Hezbollah, the group targeted the city of Inkhil in Syria. About a dozen B-1B bombers arrived at bases in Europe.
Sources: en.wikipedia.org
So far, four species from the genus Pediococcus have been isolated in wines and grape must, P. inopinatus, P. pentosaceus, P. parvulus, and P. damnosus, with the last two being the species most commonly found in wine. All Pediococcus species are Gram-positive with some species being micro-aerophilic while others utilizing mostly aerobic respiration. Under the microscope, Pediococcus often appear in pairs of pairs or tetrads which can make them identifiable. Pediococci are homofermenters, metabolizing glucose into a racemic mixture of both L- and D-lactate by glycolysis. However, in the absence of glucose, some species, such as P. pentosaceus, begin using glycerol, degrading it into pyruvate which later can be converted to diacetyl, acetate, 2,3-butanediol and other compounds that can impart unfavorable characteristics to the wine. Most Pediococcus species are undesirable in winemaking due to the high levels of diacetyl that can be produced, as well as increased production of biogenic amines that has been implicated as one potential cause for red wine headaches. Many species of Pediococcus also have the potential to introduce off odors or other wine faults to the wine such as the bitter-tasting "acrolein taint" that comes from degradation of glycerol into acrolein which then reacts with phenolic compounds in the wine to produce a bitter-tasting compound. One species, P.
== See also == List of major Lucha Libre AAA Worldwide events List of AEW PPV events List of ECW supercards and PPV events List of FMW supercards and PPV events List of GFW specials and PPV events List of MLW specials and PPV events List of NWA PPV events List of major NJPW events List of ROH PPV events List of TNA / Impact Wrestling PPV events List of TNA+ Specials List of WCCW supercard events List of WCW closed-circuit events and PPV events List of WCW Clash of the Champions shows List of WWE Saturday Night's Main Event shows List of WWE Tribute to the Troops shows
Newman stated in September 2015 that a sequel to Garry's Mod was in early development, with Newman looking to include virtual reality content and choose a name other than "Garry's Mod 2". He later announced S&box, a sandbox game using Unreal Engine 4, in September 2017 as a potential spiritual successor to Garry's Mod. By December 2019, development on the game had been paused. Newman resumed development in March 2020 and later moved it to the Source 2 engine. S&box was released on 28 April 2026, to mixed reviews.
== Global demand == Global EO demand has expanded from 16.6 Mt (18.3 million short tons) in 2004 to 20 Mt (22 million short tons) in 2009, while demand for refined EO expanded from 4.64 Mt (5.11 million short tons) in 2004 to 5.6 Mt (6.2 million short tons) in 2008. In 2009, demand is estimated to have declined to about 5.2 Mt (5.7 million short tons). Total EO demand registered a growth rate of 5.6% per annum during the period 2005 to 2009 and is projected to grow at 5.7% per annum during 2009 to 2013.
Board of directors. Jo Coburn (born 12 November 1967); broadcaster and journalist with BBC News, married to former Downing Street head of strategic communications Mark Flanagan; regular presenter of Politics Live (and formerly also Sunday Politics along with Andrew Neil) and previously had special responsibility for BBC Breakfast; former BBC political correspondent for London, who covered the 2000 London Mayoral election; occasional relief presenter on the BBC News Channel. She has presented on BBC Radio 4 in the past and also has guested on the weekend current affairs programme The World This Weekend as well as reviewing the Sunday newspapers on The Andrew Marr Show. Benjamin Cohen (journalist) (born 14 August 1982), web developer, entrepreneur and online publisher; founder of LGBT news site PinkNews;from 2006 until 2012 was technology correspondent for Channel 4 News. He is the Chief Executive of PinkNews, and regularly writes for the London Evening Standard. Dave Cohen (writer); writer for television and radio as well as contributing columns to NME, Chortle and The Huffington Post.; has written for BBC Radio 4 including The Best of British, Dead Ringers which won a Sony Gold Award 2001, The Sunday Format, The News Quiz and 15 Minute Musical which he was also a co-creator and won the 2009 Writer's Guild Best Radio Comedy Show, to name a few. He also wrote for BBC Radio 5's The Treatment and They Came From Nowhere; has written for Rory Bremner Show, Spitting Image, Eleven O'Clock Show, Not Going Out and My Family.
Sources: en.wikipedia.org
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.
The peptide was named after a protein fraction found in human gastric juice, and the shorter form was called body protection compound. That phrase was shortened to the abbreviation BPC. The number 157 refers to a laboratory designation used in the original isolation work.
Its sequence corresponds to a segment of a protein present in gastric secretions, but the material supplied for research is made synthetically. No commercial product is purified from human or animal tissue. The synthetic route is used because it gives a defined chain length and a reproducible sequence.
Reversed-phase liquid chromatography with ultraviolet detection gives a purity estimate, while mass spectrometry confirms molecular mass and flags modifications. Amino acid analysis can add compositional confirmation. Results are most meaningful when a validated reference standard is run alongside the sample.